BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives FDA Peptide Reclassification 2026: What It Means for Providers The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA mulls compounding for peptides previously flagged over safety risks BioSpace Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review